Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses.
There are legitimate concerns that the highly pathogenic H5N1 avian influenza virus could adapt for human-to-human transmission and cause a pandemic similar to the 1918 "Spanish flu" that killed 50 million people worldwide. We have developed pandemic influenza vaccines by incorporating multiple antigens from both avian and Spanish influenza viruses into complex recombinant adenovirus vectors. In vaccinated mice, these vaccines induced strong humoral and cellular immune responses against pandemic influenza virus antigens, and protected vaccinated mice against lethal H5N1 virus challenge. These results indicate that this multi-antigen, broadly protective vaccine may serve as a safer and more effective approach than traditional methods for development of a pandemic influenza vaccine.
Holman
David H
DH
Division of Biodefense Vaccines, GenPhar Inc., 600 Seacoast Parkway, Mount Pleasant, SC 29464, USA.
Wang
Danher
D
Raja
Nicholas U
NU
Luo
Min
M
Moore
Kevin M
KM
Woraratanadharm
Jan
J
Mytle
Nutan
N
Dong
John Y
JY
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000956:Antigens, Viral / Q000276:immunology*; D001835:Body Weight; D005822:Genetic Vectors; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology*; D008297:Male; D051379:Mice; D009976:Orthomyxoviridae Infections / Q000517:prevention & control*; D016019:Survival Analysis; D013601:T-Lymphocytes / Q000276:immunology
D000914:Antibodies, Viral; D000956:Antigens, Viral; D007252:Influenza Vaccines